197 related articles for article (PubMed ID: 17161821)
1. Differential effects of single dose FTY720 on CD62L+ B-cells in stable renal allograft recipients.
Böhler T; Schütz M; Budde K; Neumayer HH; Waiser J
Int Immunopharmacol; 2007 Jan; 7(1):88-95. PubMed ID: 17161821
[TBL] [Abstract][Full Text] [Related]
2. FTY720 exerts differential effects on CD4+ and CD8+ T-lymphocyte subpopulations expressing chemokine and adhesion receptors.
Böhler T; Waiser J; Schuetz M; Neumayer HH; Budde K
Nephrol Dial Transplant; 2004 Mar; 19(3):702-13. PubMed ID: 14767029
[TBL] [Abstract][Full Text] [Related]
3. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors.
Chiba K
Pharmacol Ther; 2005 Dec; 108(3):308-19. PubMed ID: 15951022
[TBL] [Abstract][Full Text] [Related]
4. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats, III. Increase in frequency of CD62L-positive T cells in Peyer's patches by FTY720-induced lymphocyte homing.
Yanagawa Y; Masubuchi Y; Chiba K
Immunology; 1998 Dec; 95(4):591-4. PubMed ID: 9893050
[TBL] [Abstract][Full Text] [Related]
5. The S1P receptor modulator FTY720 prevents the development of experimental colitis in mice.
Deguchi Y; Andoh A; Yagi Y; Bamba S; Inatomi O; Tsujikawa T; Fujiyama Y
Oncol Rep; 2006 Oct; 16(4):699-703. PubMed ID: 16969482
[TBL] [Abstract][Full Text] [Related]
6. FTY720 preferentially depletes naive T cells from peripheral and lymphoid organs.
Hofmann M; Brinkmann V; Zerwes HG
Int Immunopharmacol; 2006 Dec; 6(13-14):1902-10. PubMed ID: 17161343
[TBL] [Abstract][Full Text] [Related]
7. Sphingosine 1-phosphate receptor agonism impairs skin dendritic cell migration and homing to secondary lymphoid tissue: association with prolonged allograft survival.
Lan YY; Tokita D; Wang Z; Wang HC; Zhan J; Brinkmann V; Thomson AW
Transpl Immunol; 2008 Nov; 20(1-2):88-94. PubMed ID: 18694829
[TBL] [Abstract][Full Text] [Related]
8. FTY720 reduces T-cell recruitment into murine intestinal allograft and prevents activation of graft-infiltrating cells.
Kimura T; Hasegawa T; Nakai H; Azuma T; Usui N; Sasaki T; Okada A
Transplantation; 2003 May; 75(9):1469-74. PubMed ID: 12792499
[TBL] [Abstract][Full Text] [Related]
9. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.
Mehling M; Brinkmann V; Antel J; Bar-Or A; Goebels N; Vedrine C; Kristofic C; Kuhle J; Lindberg RL; Kappos L
Neurology; 2008 Oct; 71(16):1261-7. PubMed ID: 18852441
[TBL] [Abstract][Full Text] [Related]
10. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing.
Chiba K; Yanagawa Y; Masubuchi Y; Kataoka H; Kawaguchi T; Ohtsuki M; Hoshino Y
J Immunol; 1998 May; 160(10):5037-44. PubMed ID: 9590253
[TBL] [Abstract][Full Text] [Related]
11. The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1.
Schmid G; Guba M; Ischenko I; Papyan A; Joka M; Schrepfer S; Bruns CJ; Jauch KW; Heeschen C; Graeb C
J Cell Biochem; 2007 May; 101(1):259-70. PubMed ID: 17203465
[TBL] [Abstract][Full Text] [Related]
12. FTY720 mediates apoptosis-independent lymphopenia in human renal allograft recipients: different effects on CD62L+ and CCR5+ T lymphocytes.
Böhler T; Waiser J; Schütz M; Dragun D; Neumayer HH; Budde K
Transplantation; 2004 May; 77(9):1424-32. PubMed ID: 15167602
[TBL] [Abstract][Full Text] [Related]
13. Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus.
Chiba K; Matsuyuki H; Maeda Y; Sugahara K
Cell Mol Immunol; 2006 Feb; 3(1):11-9. PubMed ID: 16549044
[TBL] [Abstract][Full Text] [Related]
14. Sphingosine 1-phosphate receptor agonist FTY720-phosphate causes marginal zone B cell displacement.
Vora KA; Nichols E; Porter G; Cui Y; Keohane CA; Hajdu R; Hale J; Neway W; Zaller D; Mandala S
J Leukoc Biol; 2005 Aug; 78(2):471-80. PubMed ID: 15894589
[TBL] [Abstract][Full Text] [Related]
15. The sphingosine 1-phosphate receptor agonist FTY720 potently inhibits regulatory T cell proliferation in vitro and in vivo.
Wolf AM; Eller K; Zeiser R; Dürr C; Gerlach UV; Sixt M; Markut L; Gastl G; Rosenkranz AR; Wolf D
J Immunol; 2009 Sep; 183(6):3751-60. PubMed ID: 19692647
[TBL] [Abstract][Full Text] [Related]
16. Transient T cell accumulation in lymph nodes and sustained lymphopenia in mice treated with FTY720.
Morris MA; Gibb DR; Picard F; Brinkmann V; Straume M; Ley K
Eur J Immunol; 2005 Dec; 35(12):3570-80. PubMed ID: 16285007
[TBL] [Abstract][Full Text] [Related]
17. Activity of nuclear factor of activated T cells is independent of the number of peripheral lymphocytes in FTY720-treated patients.
Sommerer C; Morath C; Giese T; Meuer S; Zeier M
Transplant Proc; 2008 Jun; 40(5):1416-8. PubMed ID: 18589120
[TBL] [Abstract][Full Text] [Related]
18. FTY720 reduces extracellular matrix expansion associated with ischemia-reperfusion induced injury.
Delbridge MS; Shrestha BM; Raftery AT; El Nahas AM; Haylor J
Transplant Proc; 2007 Dec; 39(10):2992-6. PubMed ID: 18089307
[TBL] [Abstract][Full Text] [Related]
19. Sphingosine-1-phosphate analogue FTY720 causes lymphocyte redistribution and hypercholesterolemia in ApoE-deficient mice.
Klingenberg R; Nofer JR; Rudling M; Bea F; Blessing E; Preusch M; Grone HJ; Katus HA; Hansson GK; Dengler TJ
Arterioscler Thromb Vasc Biol; 2007 Nov; 27(11):2392-9. PubMed ID: 17761943
[TBL] [Abstract][Full Text] [Related]
20. The role of the lysophospholipid sphingosine 1-phosphate in immune cell biology.
von Wenckstern H; Zimmermann K; Kleuser B
Arch Immunol Ther Exp (Warsz); 2006; 54(4):239-51. PubMed ID: 16830220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
